QUALIGEN THERAPEUTICS, INC. ANNOUNCES $8.82 MILLION COMMON STOCK REGISTERED DIRECT OFFERING
29 nov. 2021 15h50 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutic products for the treatment of cancer,...
Qualigen Therapeutics, Inc. Reports Third Quarter 2021 Financial Results
15 nov. 2021 09h00 HE
|
Qualigen Therapeutics, Inc.
Quarterly revenues increased 38% to approximately $1.2 million, compared to approximately $0.8 million in the same quarter of the previous yearYear-to-date revenues increased 30% to $4.2 million,...
Peer-Reviewed Article Confirms That Qualigen’s FastPack® is as Accurate in Thyroid Stimulating Hormone Measurement -- and Much Faster -- Than a Leading Laboratory Method
19 oct. 2021 09h00 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with...
Qualigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
15 sept. 2021 07h30 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with...
Qualigen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
08 sept. 2021 07h30 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with...
Qualigen Therapeutics, Inc. Provides Update on Product Development Priorities and Reports Second Quarter and Six Month 2021 Financial Results
17 août 2021 08h00 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif.,, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announces its intention to prioritize its focus to its oncology pipeline that includes QN-247...
Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19
14 juil. 2021 07h30 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral...
Qualigen Therapeutics Announces Inclusion in Russell Microcap® Index
08 juin 2021 07h30 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral...
Qualigen Therapeutics, Inc. to Present at the LD Micro Invitational XI Conference
02 juin 2021 07h30 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral...
Qualigen Therapeutics, Inc. Appoints Tariq Arshad, MD, MBA as Chief Medical Officer
19 mai 2021 07h30 HE
|
Qualigen Therapeutics, Inc.
New Position Created to Deepen Clinical Expertise and Advance Pipeline Therapeutic Programs CARLSBAD, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a...